The next time you reach for a Neutrogena face wash or sunscreen, you are holding a product with one of the most dramatic corporate ownership journeys in the history of American consumer goods. It started in a small Hollywood cosmetics shop in 1930, passed through the hands of one of the world’s most trusted healthcare companies, survived a landmark corporate spin-off, and is now at the center of a $48.7 billion merger that could close before the end of 2026 — one of the largest consumer health deals in modern history.
So who actually owns Neutrogena right now? Let us walk through the complete story.
What Is Neutrogena?
Neutrogena is one of the most recognized skincare brands on the planet — famous for its dermatologist-recommended products, its iconic transparent glycerin soap bar, and a product line that spans facial cleansers, moisturizers, sunscreens, acne treatments, and hair care. The brand distributes products in over 70 countries and has major subsidiaries in Canada, the United Kingdom, South Korea, and India.
Its reputation was built on one key strategic insight: position skincare as something doctors recommend, not just something celebrities endorse. That philosophy, developed in the late 1960s and early 1970s, turned a small family-owned company into a global brand worth nearly a billion dollars by the early 1990s.
Who Owns Neutrogena Right Now in 2026?
The current owner of Neutrogena is Kenvue Inc. — a publicly traded consumer health company listed on the New York Stock Exchange under the ticker symbol KVUE. Neutrogena is now part of Kenvue, the consumer health company that spun off from Johnson & Johnson in 2023.
However, Kenvue’s ownership is about to change dramatically. Kimberly-Clark announced it will acquire Kenvue in a cash-and-stock deal valuing Kenvue at an enterprise value of approximately $48.7 billion. The offer gives Kenvue holders $21.01 per share — a roughly 46% premium to the prior close. Closing is targeted for the second half of 2026, pending regulatory approvals.
Both Kimberly-Clark and Kenvue shareholders voted overwhelmingly to approve the acquisition on January 29, 2026. Once this deal closes, Neutrogena will be owned by Kimberly-Clark — the company behind Huggies, Kleenex, Cottonelle, and Kotex.
In the simplest terms possible: Kenvue owns Neutrogena today. Kimberly-Clark will own it by the end of 2026.
Ownership and Key Stakeholders Table
| Owner / Party | Role | Stake | Key Detail |
|---|---|---|---|
| Kenvue Inc. (NYSE: KVUE) | Current Direct Owner | 100% of Neutrogena brand | Spun off from J&J in 2023; world’s largest pure-play consumer health company |
| Kimberly-Clark (NASDAQ: KMB) | Pending Owner | Acquiring Kenvue for $48.7B | Deal announced Nov 2025; shareholders approved Jan 29, 2026; closing H2 2026 |
| Johnson & Johnson | Former Owner (1994–2023) | Exited via Kenvue spin-off | Acquired Neutrogena in 1994 for $924 million |
| Vanguard Group | Largest Kenvue Institutional Shareholder | Significant KVUE stake | Passive index investor; one of the biggest KVUE holders |
| BlackRock Inc. | Institutional Shareholder | Significant KVUE stake | World’s largest asset manager; major KVUE holder |
| Emanuel Stolaroff | Original Founder | No longer relevant | Founded Natone (later Neutrogena) in 1930 in Los Angeles |
| Lloyd Cotsen | Former CEO & Key Builder | No longer relevant | Built dermatologist strategy in 1960s–70s; led the brand to national fame |
The Origin Story: Hollywood, Glycerin Soap, and a Belgian Chemist
The Neutrogena story begins in Los Angeles in 1930 — not in a laboratory, but in the glamorous world of Hollywood film studios.
Emanuel Stolaroff founded a cosmetics supply company called Natone in 1930, serving beauty salons in the film industry. In 1954, Stolaroff discovered a patented, transparent liquid soap formula and began importing it to department stores and drugstores under the Neutrogena name.
Stolaroff met Belgian chemist Edmond Fromont in 1954, and acquired the rights to distribute his patented formula of a mild clear soap that cleared the skin without drying it, in the U.S. That soap — the original Neutrogena bar — became the brand’s defining product. Transparent, gentle, unscented, and unlike anything else on the drugstore shelf at the time.
The soap proved popular enough that the entire company rebranded as Neutrogena in 1962. Around this time, a man named Lloyd Cotsen — who had married into the Stolaroff family — began taking a more active role in running the business.
Lloyd Cotsen, who later became CEO, is credited with building the brand’s relationship with dermatologists during the late 1960s and early 1970s. That strategy of positioning Neutrogena as a dermatologist-recommended product line shaped the brand’s identity for decades and made it an attractive acquisition target.
The company went public in 1973. By the early 1990s, Neutrogena was a publicly traded company with a strong reputation in specialty skincare — with sales reaching $281.70 million in 1993.
Johnson & Johnson’s $924 Million Bet
By the early 1990s, every major consumer goods company in America wanted a piece of Neutrogena. The brand had something money could not easily buy — genuine credibility with dermatologists, a loyal customer base, and a premium pricing power that competitors could only envy.
Johnson & Johnson acquired Neutrogena in 1994 for approximately $924 million in an all-cash deal. That translates to roughly $2 billion in today’s money — a significant premium that reflected just how much J&J valued the brand’s dermatologist positioning and global growth potential.
Under J&J’s ownership, Johnson & Johnson’s international network helped Neutrogena boost its sales and enter newer markets including India, South Africa, and China. The brand expanded from its original soap bar into a complete skincare and haircare ecosystem — sunscreens, acne treatments, facial cleansers, moisturizers, and more — all carrying the powerful “dermatologist recommended” stamp that Cotsen had worked so hard to build.
Neutrogena spent nearly 30 years under J&J’s ownership — until everything changed in 2021.
The Kenvue Spin-Off: Neutrogena Gets a New Home
In November 2021, Johnson & Johnson announced a decision that would reshape the consumer health industry. J&J announced plans to spin off its entire consumer health division as a standalone company. The new entity was named Kenvue in September 2022. Its initial public offering took place in May 2023, but J&J initially kept more than 90% of Kenvue’s shares.
Full separation came on August 23, 2023, when J&J completed a share exchange, swapping roughly 1.53 billion shares of Kenvue stock for approximately 191 million shares of its own.
The strategic logic was straightforward: J&J wanted to focus exclusively on pharmaceuticals and medical devices, and leadership believed separating the consumer business would unlock more value for shareholders in both companies.
Kenvue launched as the world’s largest pure-play consumer health company by revenue, carrying brands including Neutrogena, Aveeno, Band-Aid, Tylenol, Listerine, Johnson’s, Visine, and Rogaine. Built on more than a century of heritage, these brands are science-backed and recommended by healthcare professionals around the world.
The $48.7 Billion Kimberly-Clark Deal: The Biggest Move Yet
Just as Kenvue was finding its footing as an independent company, another dramatic ownership change arrived — this time in the form of a $48.7 billion offer from Kimberly-Clark.
Kimberly-Clark announced it would acquire Kenvue — the maker of Neutrogena, Tylenol, Band-Aid, and Listerine — in a cash-and-stock deal valuing Kenvue at $48.7 billion. The combined company is projected to produce annual sales of $32 billion, which would make it the second largest company in the health and wellness sector by sales, behind Procter & Gamble ($54 billion) and ahead of Unilever ($31 billion).
Kimberly-Clark CEO Mike Hsu will lead the merged entity, headquartered in Irving, Texas. Cost savings from joining together are expected to be $2.1 billion, realized in the first two years after closing.
Both companies’ shareholders voted overwhelmingly to approve the deal on January 29, 2026. Kimberly-Clark expects the transaction to close by the end of 2026, and integration planning is progressing across its workstreams.
Once the deal closes, Neutrogena will sit alongside Huggies, Kleenex, Cottonelle, Kotex, and Depend inside one of the most powerful consumer goods companies on Earth.
What Other Brands Come With Kenvue?
Understanding Neutrogena’s current home means understanding what Kenvue looks like as a whole. Kenvue’s iconic brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol — all science-backed and recommended by healthcare professionals around the world.
Together, these brands generate billions in annual revenue and touch consumers across every stage of life — from Johnson’s baby products to Tylenol for everyday pain relief to Neutrogena for skincare to Listerine for oral health. It is exactly that breadth that made Kenvue attractive to Kimberly-Clark in the first place.
Frequently Asked Questions (FAQs)
Q1. Who owns Neutrogena in 2026?
Neutrogena is currently owned by Kenvue Inc. (NYSE: KVUE), the consumer health company spun off from Johnson & Johnson in 2023.
Q2. Is Neutrogena still owned by Johnson & Johnson?
No. J&J spun off all its consumer health brands — including Neutrogena — into Kenvue Inc., which became fully independent on August 23, 2023.
Q3. Who is buying Neutrogena’s parent company Kenvue?
Kimberly-Clark (NASDAQ: KMB) is acquiring Kenvue in a $48.7 billion deal expected to close by the end of 2026.
Q4. Who founded Neutrogena and when?
Neutrogena was founded by Emanuel Stolaroff in 1930 in Los Angeles under the name Natone, rebranding as Neutrogena in 1962.
Q5. How much did J&J pay for Neutrogena?
Johnson & Johnson acquired Neutrogena in 1994 for approximately $924 million in an all-cash transaction.
Q6. What brands does Kenvue own along with Neutrogena?
Kenvue also owns Aveeno, Band-Aid, Tylenol, Listerine, Johnson’s, Visine, and Rogaine.
Q7. When will Kimberly-Clark complete its Kenvue acquisition?
Both companies’ shareholders approved the deal on January 29, 2026, with the transaction expected to close by the end of 2026.
Q8. What other brands will Kimberly-Clark own after buying Kenvue?
The combined company will include Neutrogena, Tylenol, Listerine, Band-Aid, Huggies, Kleenex, Kotex, and Cottonelle — creating a $32 billion health and wellness giant.
Neutrogena has traveled a remarkable road — from a Hollywood cosmetics supplier named Natone in 1930, to a dermatologist-beloved soap brand that went public in 1973, to a $924 million acquisition by Johnson & Johnson in 1994, to its current home inside Kenvue Inc. following the 2023 spin-off.
As of 2026, Kenvue owns Neutrogena — but not for long. A $48.7 billion acquisition by Kimberly-Clark has been approved by shareholders of both companies, with closing expected before the end of 2026. When that deal completes, Neutrogena will become part of a $32 billion consumer health and wellness empire that also includes Huggies, Kleenex, Tylenol, Listerine, and Band-Aid.